The summer months have brought the biotech IPO market to a near standstill after a record run, but activity is slowly starting to ramp back up again as another company is taking the Nasdaq plunge.
ADHD drug developer Cingulate filed for an IPO on Thursday, penciling in a modest $58 million for its raise. Based out of Kansas City, KS, Cingulate has a Phase III-ready ADHD program in addition to a follow-up candidate soon to hit the clinic, as well as a third program still in early preclinical development for anxiety.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,